Shots:
GSK has entered into an agreement with Chimagen Biosciences to acquire full global rights to a trispecific T cell-engager (TCE), building on its existing relationship with Chimagen following a previous agreement to acquire CMG1A46
As per the deal, Chimagen will receive an upfront fee for Chimagen’s TCE program, with additional development & commercial milestones…
